Cutler Group’s BioXcel Therapeutics BTAI Stock Holding History

Cutler Group’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-250	Closed	-$50K	–	3644
2023 Q3	$50K	Sell	250 -25	-9%	-$2.53K	0.01%	1507
2023 Q2	$40K	Buy	+275	New	+$91.6K	0.01%	1421
2021 Q4	–	Sell	-6	Closed	-$1K	–	5395
2021 Q3	$1K	Buy	+6	New	+$2.64K	﹤0.01%	5235
2021 Q2	–	Sell	-25	Closed	-$1K	–	5712
2021 Q1	$1K	Sell	25 -69	-73%	-$55.5K	﹤0.01%	5143
2020 Q4	$10K	Sell	94 -612	-87%	-$477K	﹤0.01%	3177
2020 Q3	$27K	Buy	706 +450	+176%	+$338K	﹤0.01%	2218
2020 Q2	$14K	Sell	256 -144	-36%	-$93.9K	﹤0.01%	2619
2020 Q1	$42K	Buy	+400	New	+$144K	﹤0.01%	1831

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cutler Group's BTAI Position: Q1 2024 in Review

Cutler Group reduced its BioXcel Therapeutics (BTAI) stake by 3.1% in Q1 2024, selling an estimated $286 and leaving 188 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #1361.

Cutler Group first reported a position in BTAI in Q1 2020 and has held it in 16 quarters since. The position peaked at $519K in Q2 2020. 73 funds tracked by Wall St. Rank hold BTAI as of Q1 2024.

Cutler Group held 188 shares of BioXcel Therapeutics worth $8K as of Q1 2024.
Cutler Group sold 6 BioXcel Therapeutics shares in Q1 2024, an estimated $286.
BioXcel Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1361 holding.
Cutler Group first reported a position in BioXcel Therapeutics in Q1 2020 and has held it in 16 quarters since.
Cutler Group's BioXcel Therapeutics position peaked at $519K in Q2 2020.
73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.